WSL
KNTE

Western Standard LLC’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Western Standard LLC’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-102,780
Closed -$1.3M – 40
2022
Q2 		$1.3M Buy
+102,780
New +$957K 0.98% 28

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Western Standard LLC's KNTE Position: Q3 2022 in Review

Western Standard LLC sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q3 2022, closing a stake of 102,780 shares — an estimated $1.3M sold.

Western Standard LLC first reported a position in KNTE in Q2 2022 and held it in 1 quarter. The position peaked at $1.3M in Q2 2022. 84 funds tracked by Wall St. Rank hold KNTE as of Q3 2022.

  • Western Standard LLC reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Western Standard LLC sold 102,780 Kinnate Biopharma Inc. Common Stock shares in Q3 2022, an estimated $1.3M.
  • Western Standard LLC first reported a position in Kinnate Biopharma Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Western Standard LLC's Kinnate Biopharma Inc. Common Stock position peaked at $1.3M in Q2 2022.
  • 84 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q3 2022.

Based on Western Standard LLC's 13F filing for Q3 2022, filed 14 Nov 2022.